← Back to Search
Safety And Efficacy Of Combination Immunotherapy With Interferon Alfa-2b And Tremelimumab In Patients With Stage IV Melanoma.
A. Tarhini, John Cherian, S. Moschos, H. Tawbi, Y. Shuai, W. Gooding, C. Sander, J. Kirkwood
Published 2012 · Medicine
Download PDFAnalyze on Scholarcy
PURPOSE We tested the hypothesis that the combination of tremelimumab and interferon alfa-2b acting via different and possibly synergistic mechanisms would overcome tumor immune tolerance and lead to significant and durable clinical responses. PATIENTS AND METHODS We conducted a phase II study in which patients were administered tremelimumab 15 mg/kg/course (three cycles [one cycle = 4 weeks]) intravenously every 12 weeks. High-dose interferon alfa-2b (HDI) was administered concurrently, including intravenous induction at 20 MU/m2/d for 5 d/wk for 4 weeks followed by maintenance at 10 MU/m2/d subcutaneously three times a week for 8 weeks per course. From course 2 onward, HDI maintenance was administered subcutaneously. RESULTS Thirty-seven patients with American Joint Committee on Cancer stage IV (9M1a, 6M1b, and 22M1c) were enrolled. Two patients had previously treated brain metastases. Grades 3 and 4 toxicities included neutropenia (six patients; 17%), diarrhea/colitis (four patients; 11%), liver enzyme increase (four patients; 11%), rash (four patients; 11%), fatigue (15 patients; 40%), and anxiety/depression (five patients; 14%). Response data were available for 35 patients. The best objective response rate (RR; Response Evaluation Criteria in Solid Tumors) by intention to treat was 24% (90% CI, 13% to 36%; four complete responses [CRs] and five partial responses [PRs] that lasted 6, 6, > 12, > 14, > 18, 20, > 28, 30, and > 37 months, respectively). Fourteen patients (38%) had stable disease (SD) that lasted 1.5 to 21 months. The median progression-free survival was 6.4 months (95% CI, 3.3 to 12.1 months). The median overall survival (OS) was 21 months (95% CI, 9.5 to not reached). There was a weak association between therapy-induced autoimmunity and clinical benefits (CR/PR/SD; P = .0059), baseline C-reactive protein (CRP) less than or equal to 2.7× the upper limit of normal and clinical benefits (P = .0494) and improved probability of survival (P = .0032), and baseline lymphocyte count of at least 1,000/μL and response (CR/PR; P = .0183) and clinical benefits (CR/PR/SD; P = .0255). Biomarker associations were not significant after adjustment for multiple comparisons. CONCLUSION HDI can be administered combined with tremelimumab with acceptable toxicity and promising durable antitumor efficacy that warrant further testing in a randomized trial.
This paper references
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment
J. Wolchok (2008)
Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development.
C. A. Wenner (1996)
Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?
Helena Enocsson (2009)
CD 28-Regulated Activation of Th 2 Responses Knockout Mice Is Characterized by Lymphoproliferative Disorder in CTLA-4
R. Khattri (1999)
Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma.
M. A. Marshall (2010)
ulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high - dose IFNalpha 2 b
W Wang (2007)
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E. Tivol (1995)
Selective Expression of an Interleukin-12 Receptor Component by Human T Helper 1 Cells
L. Rogge (1997)
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
J. Kirkwood (1996)
Next generation of immunotherapy for melanoma.
J. Kirkwood (2008)
Lymphoproliferative disorder in CTLA-4 knockout mice is characterized by CD28-regulated activation of Th2 responses.
R. Khattri (1999)
Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment.
N. Weijl (1993)
Type I Interferon as a Link Between Innate and Adaptive Immunity through Dendritic Cell Stimulation
D. Tough (2004)
Interferon‐alpha (IFN‐α) stimulates anti‐melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC)
K. J. Palmer (2000)
Elimi - nation of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte - associated antigen 4 ( CTLA - 4 ) blockade immunother
ED Kwon (1999)
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma.
G. Phan (2001)
Thyroid Dysfunction in 281 Patients with Metastatic Melanoma or Renal Carcinoma Treated with Interleukin‐2 Alone
R. S. Krouse (1995)
Myeloid-derived suppressor cells as regulators of the immune system
D. Gabrilovich (2009)
Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study
O. Hamid (2008)
Interferon‐alpha‐2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder
Joaquín A. Carballido (1993)
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
A. Ribas (2005)
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
P. Waterhouse (1995)
Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocyte-derived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities.
S. Parlato (2001)
Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
A. Hurwitz (2000)
Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials.
E. Korn (2008)
Primary hypothyroidism associated with interleukin-2 and interferon alpha-2 therapy of melanoma and renal carcinoma.
S. Scalzo (1990)
Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-α2b
Z. Yurkovetsky (2007)
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation
M. Krummel (1995)
Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.
Kristin M. Sanderson (2005)
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.
J. Wolchok (2010)
A phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
J. Kirkwood (2008)
Interferon‐α and granulocyte‐macrophage colony‐stimulating factor differentiate peripheral blood monocytes into potent antigen‐presenting cells
R. Paquette (1998)
Modulation of Signal Transducers and Activators of Transcription 1 and 3 Signaling in Melanoma by High-Dose IFNα2b
W. Wang (2007)
Myeloid - derived suppressor cells as regulators of the immune sys
DI Gabrilovich (2009)
Interleukin-10 and Transforming Growth Factor-B1Mediates Suppression in the Tumor Microenvironment
Laura Strauss (2007)
Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
S. Moschos (2006)
Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma
A. Ribas (2008)
Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma
A. Hauschild (2008)
Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells
V. Brinkmann (1993)
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma
L. Naldi (1995)
Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy.
J. Kirkwood (2002)
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
T. Eberlein (2012)
C-reactive protein: ligands, receptors and role in inflammation.
L. Marnell (2005)
Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206.
D. C. Hanson (2004)
Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-Dioxygenase (IDO) Expression With the CTLA4 Blocking MAB CP-675,206
A. Ribas (2006)
Prognostic significance of autoimmunity during treatment of melanoma with interferon
M. Krauze (2011)
Patients With Renal Cell Carcinoma or Melanoma
T. Tatsumi (2002)
Antiphospholipid syndrome associated with immunotherapy for patients with melanoma.
J. Becker (1993)
Interferon alfa-induced autoimmunity and serum S100 levels as predictive and prognostic biomarkers in high-risk melanoma in the ECOG-intergroup phase II trial E2696
Joseph Stuckert (2007)
Association of baseline and on-study tumor biopsy markers with clinical activity in patients (pts) with advanced melanoma treated with ipilimumab.
O. Hamid (2009)
Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.
S. Rosenberg (1996)
Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer.
A. Franzke (1999)
Combination Immunotherapy of B16 Melanoma Using Anti–Cytotoxic T Lymphocyte–Associated Antigen 4 (Ctla-4) and Granulocyte/Macrophage Colony-Stimulating Factor (Gm-Csf)-Producing Vaccines Induces Rejection of Subcutaneous and Metastatic Tumors Accompanied by Autoimmune Depigmentation
A. van Elsas (1999)
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.
M. Atkins (1988)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
G. Phan (2003)
A new member of the immunoglobulin superfamily—CTLA-4
J. Brunet (1987)
Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690.
J. Kirkwood (2002)
Diagnosing melanoma patients entering American Joint Committee on Cancer stage IV, C-reactive protein in serum is superior to lactate dehydrogenase
M. Deichmann (2004)
Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.
E. Kwon (1999)
Cytotoxic T Lymphocyte Antigen 4 (CTLA4) Blockade Accelerates the Acute Rejection of Cardiac Allografts in CD28-deficient Mice: CTLA4 Can Function Independently of CD28
H. Lin (1998)
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Tremelimumab (CP-675,206): a fully human anticytotoxic T lymphocyte-associated antigen 4 monoclonal antibody for treatment of patients with advanced cancers.
A. Tarhini (2008)
The critical role of Th1-dominant immunity in tumor immunology
T. Nishimura (2000)
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.
G. Dranoff (1993)
This paper is referenced by
Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
A. Tarhini (2014)
Immunotherapy of cancer in 2012
J. Kirkwood (2012)
CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
P. Ott (2013)
How much of a good thing? What duration for interferon alfa-2b adjuvant therapy?
A. Tarhini (2012)
Trial Watch: Monoclonal antibodies in cancer therapy
L. Galluzzi (2012)
Der Einfluss des koinhibitorischen Rezeptors PD-1 (Programmed death-1) auf die Effizienz einer vakzine-induzierten CD8 + T-Zell Antwort
Fachbereichs Biologie (2013)
CYTOKINES AND INTERFERONS
R. J. Ho (2013)
Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment
Bárbara Carreira (2020)
A phase 2 study of tremelimumab in patients with advanced uveal melanoma
A. Joshua (2015)
Engineering immunity : enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer
K. Moynihan (2017)
Tumor-infiltrating lymphocytes and their significance in melanoma prognosis.
T. Schatton (2014)
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study.
R. Alvarez (2014)
Metastatic melanoma – a review of current and future drugs
T. Velho (2012)
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma.
Ragini R. Kudchadkar (2013)
A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma
A. Brohl (2016)
IFN-α in the Treatment of Melanoma
A. Tarhini (2012)
Risk Reductions of Recurrence and Mortality in Melanoma Patients Using IFN-α
Ahmad A Tarhini (2016)
Enhancing the Efficacy of Checkpoint Blockade Through Combination Therapies
Vikram R. Juneja (2016)
Combination therapy strategies for improving PD‐1 blockade efficacy: a new era in cancer immunotherapy
P. S. Chowdhury (2018)
Monoclonal Antibodies to CTLA-4 with Focus on Ipilimumab
G. Graziani (2014)
Immune checkpoint modulation: rational design of combination strategies.
D. Zamarin (2015)
Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
A. Eggermont (2015)
This information is current as in the Treatment of Melanoma α IFN -
A. Tarhini (2012)
FUTURE PERSPECTIVES IN MELANOMA RESEARCH. Meeting report from the “Melanoma Research: a bridge from Naples to the World. Napoli, December 5th–6 th2011”
P. Ascierto (2012)
Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1
E. Simeone (2012)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
P. Hegde (2016)
C-reactive protein as a marker of melanoma progression.
Shenying Fang (2015)
The use of immunotherapy in the treatment of melanoma
Tala Achkar (2017)
CTLA-4 blockade and the renaissance of cancer immunotherapy.
S. Mocellin (2013)
Adjuvant Therapy for High-Risk Melanoma
A. Tarhini (2014)
Immunotherapy in the management of melanoma: current status
D. Alston (2013)
Downregulation of RIG-I mediated by ITGB3/c-SRC/STAT3 signaling confers resistance to interferon-α-induced apoptosis in tumor-repopulating cells of melanoma
Y. Li (2020)See more